The role of 3-D printing in transforming the practice of radiology will be highlighted during the Radiological Society of North America's annual meeting in Chicago, which runs through Dec. 1.
Hostilities are intensifying in the misbegotten matchup of Abbott Laboratories and Alere. The two medical products companies haven't stopped fighting since shortly after Abbott agreed in January to buy Alere for $5.8 billion.
A serious commitment to “doubling the pace” of progress will require the public and private sectors to consider doubling investments in medical research to about $1,000 per American per year to find the solutions to what ails us.
Despite the slew of new partnerships and initiatives, efforts to accelerate cancer research still face obstacles on several fronts, the vice president said in a report Monday.
Detroit's Henry Ford Health System has been selected as one of several provider organizations to receive a share of a five-year, $5.5 million federal grant to lead data collection on a project that is part of the human genome research and precision medicine program.
Embattled blood testing company Theranos says it will shut down its clinical labs and wellness centers and lay off more than 40% of its full-time employees.
Now 55 cases filed in California against the pharmaceutical company Bayer can proceed before a single judge.
Patient satisfaction isn't just about the way patients are treated by physicians and staff. The equipment and products used in healthcare facilities can have a significant impact on patient opinion, according to an industry report.
Abbott waffled on its commitment to purchase Alere in April because of concerns about the accuracy of Alere's statements and representations in the agreement. The North Chicago, Ill., company this month warned that it may not go through with the proposal.
Michigan's Bureau of Community and Health Systems opened the investigation after the Detroit News reported doctors had repeatedly voiced concerns about dirty surgical instruments.
The controversy surrounding Mylan's EpiPen pricing suggests drugmakers have been slow to adapt to an environment in which millions of Americans must pay thousands of dollars out of pocket before their coverage kicks in.
Guardant Health, based in Redwood City, Calif., developed a liquid biopsy blood test that has helped match cancer patients with clinical trials and treatment options without costly or invasive biopsies. CEO and co-founder Helmy Eltoukhy calls it a “game changer” for oncology.